Navigation Links
New Anti-Clotting Drug Less Risky For Heart Attack Patients

A new study has found anti-clotting drug called bivalirudin (Angiomax) that beats the standard combination drug therapy for patients with acute coronary syndromes such as heart// attacks. This new blood thinner seems to be less risky for patients suffering from acute coronary syndromes.

The Results of the ‘Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial’ were published in November issue of the New England Journal of Medicine. The Medicines Company and Nycomed, which market Angiomax, funded the study. A team lead by Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education are conducting the research.

Dr. Stone said: "We use bivalirudin at Columbia in the vast majority of cases and have found out that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

The journal described a trial that involved around 14,000 patients with heart attack or other acute coronary syndromes. The patients were assigned to one of three drug regimens: a package treatment including heparin; a similar package including bivalirudin; or bivalirudin alone. The results showed that the patients treated with Angiomax, also known as bivalirudin, had similar rates of serious complications, such as death, heart attack and repeat artery clearing procedures as the other groups, but had significantly lower rates of serious bleeding.

Only 3 percent of those getting bivalirudin alone had major bleeding episodes comparing to that of 5.7 percent of those getting the heparin package, for patients, that makes all the difference, Stone said. Moreover, the researchers were able find that the incidences of artery blockages or major bleeding were also reduced by the usage of bivalirudin by about 14 percent compared to a drug package including heparin.

"The big difference was the reduction of major bleeding, almost 50 percent," Stone added. "Major bleeding has been associated with higher mortality, so it is important that bivalirudin, which reduced the risk of major bleeding up to 47 percent, could be reserved for patients with history of bleeding such as anemia.” – He added.

To conclude, the drug has been currently approved as a replacement for heparin in all nonemergency angioplasty procedures.

Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Herbal Remedy Risky for Cancer Patients
3. Risky Drugs To Be Avoided In The Elderly
4. HRT Not That Risky For Breast Cancer
5. Coffee In Pregnancy May Be Risky: Study
6. Distinct Brain Sections Are Activated While Making Risky Decisions
7. Americans Avoiding Risky Foods
8. Heavy Dosage Of Vitamin Supplements May Be Risky For Pregnant Women
9. Males Show More Risky Behaviour with Alcohol
10. Risky Behavior In Teenagers Leads To Depression
11. Insight Into The Risky Health Decisions On Bird Flu
Post Your Comments:

(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ( ... Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise in ... Demand " report to their offering. ... Boston scientific and others. ... including Medtronic, Biotronik, Boston scientific and ...
Breaking Medicine Technology: